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Review Article
Thrombolytic therapy in Cerebral Venous Sinus Thrombosis
Ayeesha K. Kamal
Department of Medicine, The Aga Khan University Hospital, Karachi. 
Abstract
The use of thrombolytic agents to rapidly lyse the
clot has emerged as a therapeutic modality, in concert with
interventional neuroradiologic approaches to deliver the
agent locally at the site of thrombosis.There are no random-
ized, double blind, placebo, controlled trials to support
thrombolysis as a first line therapy in patients with cerebral
venous sinus thrombosis compared to standard therapy
using anticoagulation with  weight based dose adjusted
unfractionated Heparin. Numerous case reports and a single
non randomized trial have shown that it is comparatively
safe and may rescue patients who are deteriorating despite
anticoagulation with unfractionated Heparin. Consideration
must be given to the use of thrombolysis in this group. This
is an approach that must be restricted to centers with consid-
erable experience in neurointerventional therapy. 
Introduction
Cerebral Venous Thrombosis (CVT) is a rare disor-
der with protean manifestations. It was associated with a
mortality rate of 20% to 50% in older studies.1 However,
with the advent of MR venography, its wide range of mani-
festations, from relatively benign isolated pseudotumour
like syndrome to coma with malignant uncontrollable ICP
have begun to be recognized. It is now believed that the
mortality rate for CVT ranges from 11% to 30%.2 Thus the
prognosis is not uniformly poor.
The widespread accepted treatment for CVT is sys-
temic anticoagulation with Heparin or Heparinoid
(LMWH).Anticoagulation is believed to be beneficial as it
possibly prevents further venous clot propagation. It is not
known, given the variability and unpredictable course of the
disease, whether this mode of treatment will prevent pro-
gression in all patients. 
Thrombolytic administration represents an alternate
mode of therapy which may be used for patients with pro-
gression despite adequate anticoagulation, those with mas-
sive parenchymal haemorrhages to minimize the dose of
systemic anticoagulation, those with poor prognostic factors
on presentation, and finally those where the course is felt to
be unpredictable with potentially dangerous deterioration. 
Thrombolytics or fibrinolytics are agents which lyse
the formed clot. The platelet - fibrin composition of a spe-
cific thrombus depends on the local development of fibrin,
platelet activation, and regional blood flow. At arterial flow
rates, thrombi are predominantly platelet rich, and at venous
flow rates, more relevant to the pathology of CVT, coagula-
tion seems to predominate. Thrombin (Factor II a) cleaves
fibrinogen to form fibrin which is the scaffolding for the
clot. Thrombus growth is limited by the endogenous fibri-
nolytic system. This system is composed of plasminogen,
Plasminogen Activators (PA) and their inhibitors. Plasmin
mediates the degradation of fibrin. All fibrinolytic agents
are essentially obligate plasminogen activators that have
variable electivity for clot bound fibrin. The two most com-
mon agents reportedly used in the setting of CVT are uroki-
nase and recombinant tissue plasminogen activator (rTPA). 
The first report of systemic thrombolytic administra-
tion for CVT is from 1971.3 This idea is not novel. The
development of neuroendovascular techniques has enabled
the possibility of direct lytic administration into the affect-
ed sinus with mechanical or rheolytic aspiration of the clot.
The clinical rationale for this approach is that the clot is
removed and the occluded sinus is opened rapidly during
the procedure. This rapid decanalization may potentially
improve the clinical outcome and decrease the morbidity
and secondary complications associated with CVT.
There are no randomized, double blind, prospective,
placebo controlled trials evaluating this approach to stan-
dard systemic anticoagulation. Canhao et al have reviewed
the literature until 2001, reporting 72 publications, involv-
ing 169 patients.4 One third of these patients had some
haemorrhage on their pretreatment CT or MRI scans,
whereas 32% of these patients were in coma. These case
series are non uniform and the treatment has been utilized in
both deteriorating patients plus those who had a good neu-
rologic status but a large clot burden on angiogram.
Urokinase was the thrombolytic most frequently adminis-
tered (76%). In the majority of cases the thrombolytic was
locally infused in the occluded sinus (88%). At discharge,
11 cases (7%; 95% CI 3-12%) were dependent and 9 cases
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in 5% they were associate with clinical deterioration.
Extracranial haemorrhages occurred in 21%, but only 2%
required blood transfusion. The mortality rate of 9% is com-
parable with that of the European trial with LMWH (9%)
and compares favorably with the 7% in the heparin group of
the trial.  
A single retrospective non randomized trial com-
pared the outcomes of CVT treated by local urokinase
administration vs. dose adjusted heparin in 40 patients .The
patients were well matched for baseline factors , pretreat-
ment neurologic function was slightly worse in the throm-
bolysis group. There were no deaths in either group. At dis-
charge, 16 / 20 patients who received urokinase were neuro-
logically normal vs. 9 / 20 in those treated with heparin. The
long term follow up is not reported. This group concluded
that the treatment was at least safe and possibly effective.5
The following table (Table 1)  summarizes some of the case
series that used thrombolysis for CVST, most show flow
restoration and atleast no increase in mortality with the use
of these agents.
Another adjunctive approach that should be dis-
cussed in this context is the use of mechanical disruption,
Study Therapy Subjects Venous Flow Restorationafter therapy Outcomes and Complication
Wasay, et al 20015 Direct Urokinase vs.
Systemic Heparin 
N=40
Urokinase ( n=20)
Heparin (n=20) 
Retrospective Comparison 
Urokinase group had better dis-
charge neurologic function.
No deaths were attributed to either
Urokinase or Heparin.
Frey, et al 19997 Direct TPA and I.V.
heparin 
N=12
Case Series
Pretreatment ICH 3/12
Full in 6/12 partial in 3/12
Failed in 3/12
S/SX improved in full and
partial flow
2/3 failed flow restoration had wors-
ening ICH
1/3 tx stopped drop in fbrinogen
Kim & Suh 19978 Direct TPA N=9
Case series
Flow restored full 9/9 No haemorrhage or reocclusion 
Horowitz, et al 19959 Direct Urokinase N=12
Case Series
Pretreatment ICH 4/12
Flow restored full in 7/12
Partial in 4/12
Failed in 1/12
No haemorrhage or reocclusion
Spearman, et al 
199710
Direct Urokinase N=2
Case report
Flow restored full in 2/2 No haemorrhage  or reocclusion
Gartzen, et all 199711 Direct Urokinase fol-
lowed by I.V. heparin
N=1
Case report
Flow restored No haemorrhage or reocclusion
Di rocco, et al 198112 Urokinase and heparin N=5
Case series
Flow restored in all Full recovery in all
Table 1. Thrombolytic Therapy for CVT.
Study Therapy Subjects Venous Flow Restorationafter therapy Outcome and complication
Baker et al 200113 Combined pharmalogical
(Urokinase/ heparin) and one
or mechanical (rheolytic and
ballon catheters) clot disrup-
ton 
N=5
Urokinase
Treatment N=4/5
Mechanical disruption alone
N=1/5
Immediate improvement on
imaging studies N=5/5
Single intervention N=2/5
Two interventions N= 2/5
Multiple (5) interventions
N=1/5
Complete recovery N=2/5
Residual neurologic deficit
N=2/5
Significant neurologic deficit
N= 1/5
Chow et al 200014 Mechanical (angiolytic- rhe-
olytic) thrombectomy with
intra-artrial thrombolysis and
failed heparin
N=2
Pretreatment ICH
N=2/2
Flow restored full in 2/2 No reported haemorrhage or
occlusion 
Good neurological outcome
Phillips et al 199515 Peri-thrombus Urokinase
infusion with mechanical wire
microsnare maceration of
thrombus
N=6 groups 
Urokinase N=4
Urokinase + mechanical 
Maceration N=2
Flow restored 6/6 No reported haemorrhage or
occlusion 
Good neurological outcome
Table 2. Mechanical thrombus disruption after incomplete or failed thrombolysis.
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clot maceration and rheolytic suction to aspirate venous
clot. The application of the AngioJet catheter to the treat-
ment of dural sinus thrombosis has many potential benefits.
First, the AngioJet catheter is one of the few available
options when high doses of thrombolytic agents are con-
traindicated. Even locally delivered thrombolytic agents can
require a substantial amount of time to completely lyse a
massive clot; previous studies have documented throm-
bolytic infusions of 88 to 244 hours. Because the walls of
the sinuses are thick dura mater, with a low risk of rupture,
catheterization of all sinuses with the AngioJet catheter is
relatively safe. This is not the case, however, for cerebral
veins or the vein of Galen. The walls of these structures are
thin and fragile and associated with an increased risk of rup-
ture and cerebral haemorrhage. Therefore, thrombi in these
locations should not be treated with the AngioJet and are
ideally lysed with the direct infusion of thrombolytic agents
such as urokinase. Table 2 Summarizes the data emerging
from some of the studies employing a mechanical approach
to lysis. 
In terms of comparing anticoagulation with the use
of an interventional approach, both the approaches have
their value; the immediate administration of systemic anti-
coagulation is rapid, safe and does not require any special
skills. The majority of patients will show benefit from this
intervention. However,  those who have poor prognostic
factors6 e.g. coma, refractory ICP, DVT associated with
malignancy or infection, involvement of deep venous sys-
tem , lack of venous collaterals may stand to benefit most
from early intervention. 
Inherent in the interventional approach are the
unique complications of femoral puncture and cerebral
angiography which must be factored in the calculation of
risk/benefit decisions for these already sick patients. These
include local haemorrhage, retroperitoneal haemorrhage,
femoral pseudo aneurysm, stroke induced by angiography
and local extension of cerebral ICH.
It seems that the use of thrombolytics is at least safe
and in experienced centers, effective for those with a poor
prognosis. A large international multicenter trial comparing
the two treatments is warranted. 
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